Fatigue - Pipeline Review, H2 2013

Market: Pharmaceuticals and Healthcare

Global, 59 pages report, published by Global Markets Direct

Keywords : Fatigue Therapeutic Products under Development, Key Players in Fatigue Therapeutics, Fatigue Pipeline Overview, Fatigue Pipeline, Fatigue Pipeline Assessment

Report ThumbnailSeptember-2013
Fatigue - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Fatigue - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Fatigue, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Fatigue. Fatigue - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Fatigue.
- A review of the Fatigue products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Fatigue pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Fatigue.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Fatigue pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
  • List of Figures
  • Number of Products under Development for Fatigue, H2 2013 8
  • Products under Development for Fatigue - Comparative Analysis, H2 2013 9
  • Products under Development by Companies, H2 2013 10
  • Products under Investigation by Universities/Institutes, H2 2013 11
  • Late Stage Products, H2 2013 12
  • Mid Clinical Stage Products, H2 2013 13
  • Early Clinical Stage Products, H2 2013 14
  • Pre-Clinical Stage Products, H2 2013 15
  • Assessment by Monotherapy Products, H2 2013 23
  • Assessment by Combination Products, H2 2013 24
  • Assessment by Route of Administration, H2 2013 25
  • Assessment by Stage and Route of Administration, H2 2013 26
  • Assessment by Molecule Type, H2 2013 27
  • Assessment by Stage and Molecule Type, H2 2013 28
  • List of Tables
  • Number of Products Under Development for Fatigue, H2 2013 8
  • Products under Development for Fatigue - Comparative Analysis, H2 2013 9
  • Number of Products under Development by Companies, H2 2013 10
  • Number of Products under Investigation by Universities/Institutes, H2 2013 11
  • Comparative Analysis by Late Stage Development, H2 2013 12
  • Comparative Analysis by Mid Clinical Stage Development, H2 2013 13
  • Comparative Analysis by Early Clinical Stage Development, H2 2013 14
  • Comparative Analysis by Pre-Clinical Stage Development, H2 2013 15
  • Products under Development by Companies, H2 2013 16
  • Products under Investigation by Universities/Institutes, H2 2013 17
  • Athersys, Inc., H2 2013 18
  • Sigma-Tau S.p.A., H2 2013 19
  • Hemispherx Biopharma, Inc., H2 2013 20
  • MultiCell Technologies, Inc., H2 2013 21
  • Adamas Pharmaceuticals, Inc., H2 2013 22
  • Assessment by Monotherapy Products, H2 2013 23
  • Assessment by Combination Products, H2 2013 24
  • Assessment by Stage and Route of Administration, H2 2013 26
  • Assessment by Stage and Molecule Type, H2 2013 28
  • Fatigue Therapeutics - Drug Profile Updates 42
  • Fatigue Therapeutics - Dormant Products 49
  • Table of Contents
  • Table of Contents 2
  • List of Tables 4
  • List of Figures 5
  • Introduction 6
  • Global Markets Direct Report Coverage 6
  • Fatigue Overview 7
  • Therapeutics Development 8
  • An Overview of Pipeline Products for Fatigue 8
  • Fatigue Therapeutics under Development by Companies 10
  • Fatigue Therapeutics under Investigation by Universities/Institutes 11
  • Late Stage Products 12
  • Comparative Analysis 12
  • Mid Clinical Stage Products 13
  • Comparative Analysis 13
  • Early Clinical Stage Products 14
  • Comparative Analysis 14
  • Pre-Clinical Stage Products 15
  • Comparative Analysis 15
  • Fatigue Therapeutics - Products under Development by Companies 16
  • Fatigue Therapeutics - Products under Investigation by Universities/Institutes 17
  • Companies Involved in Fatigue Therapeutics Development 18
  • Athersys, Inc. 18
  • Sigma-Tau S.p.A. 19
  • Hemispherx Biopharma, Inc. 20
  • MultiCell Technologies, Inc. 21
  • Adamas Pharmaceuticals, Inc. 22
  • Fatigue - Therapeutics Assessment 23
  • Assessment by Monotherapy Products 23
  • Assessment by Combination Products 24
  • Assessment by Route of Administration 25
  • Assessment by Molecule Type 27
  • Drug Profiles 29
  • Histamine H3 Receptor Antagonists - Drug Profile 29
  • Product Description 29
  • Mechanism of Action 29
  • R&D Progress 29
  • rintatolimod - Drug Profile 30
  • Product Description 30
  • Mechanism of Action 30
  • R&D Progress 30
  • rintatolimod - Drug Profile 32
  • Product Description 32
  • Mechanism of Action 32
  • R&D Progress 32
  • (lofepramine + phenylalanine) - Drug Profile 34
  • Product Description 34
  • Mechanism of Action 34
  • R&D Progress 34
  • anakinra - Drug Profile 35
  • Product Description 35
  • Mechanism of Action 35
  • R&D Progress 35
  • curcumin - Drug Profile 36
  • Product Description 36
  • Mechanism of Action 36
  • R&D Progress 36
  • rituximab - Drug Profile 37
  • Product Description 37
  • Mechanism of Action 37
  • R&D Progress 37
  • clonidine - Drug Profile 38
  • Product Description 38
  • Mechanism of Action 38
  • R&D Progress 38
  • aspirin - Drug Profile 39
  • Product Description 39
  • Mechanism of Action 39
  • R&D Progress 39
  • acetyl-L-carnitine - Drug Profile 40
  • Product Description 40
  • Mechanism of Action 40
  • R&D Progress 40
  • Fatigue Therapeutics - Drug Profile Updates 42
  • Fatigue Therapeutics - Dormant Products 49
  • Fatigue - Product Development Milestones 50
  • Featured News & Press Releases 50
  • Feb 04, 2013: Hemispherx Biopharma Fails To Win FDA Approval For Its Chronic Fatigue Drug Ampligen 50
  • Dec 21, 2012: Hemispherx Biopharma Announces Outcome Of FDA Meeting On Ampligen 51
  • Oct 22, 2012: Hemispherx Biopharma Announces FDA Confirms Advisory Committee Meeting On December 20, 2012 51
  • Sep 24, 2012: Hemispherx Biopharma Announces FDA Advisory Committee Will Review Ampligen For Chronic Fatigue Syndrome 52
  • Aug 14, 2012: FDA Accepts Complete Response Submission Regarding Ampligen New Drug Application For Chronic Fatigue Syndrome 52
  • Aug 01, 2012: Hemispherx Files Complete Response With FDA Regarding Ampligen NDA For Chronic Fatigue Syndrome 53
  • Jul 18, 2012: Hemispherx Biopharma Files New Drug Application In Argentina For Ampligen To Treat Chronic Fatigue Syndrome 54
  • Jul 11, 2012: Hemispherx And FDA Reach Agreement On Filing Requirements For Complete Response In Support Of Ampligen NDA For Chronic Fatigue Syndrome Treatment 55
  • Jun 12, 2012: Dr Micheal Hedenus To Present Promising Results From Clinical Study Of Ferric Carboxymaltose At 17th Congress Of EHA 56
  • Apr 17, 2012: Galenica Announces Results Of Ferinject Clinical Study 57
  • Appendix 58
  • Methodology 58
  • Coverage 58
  • Secondary Research 58
  • Primary Research 58
  • Expert Panel Validation 58
  • Contact Us 59
  • Disclaimer 59

Please select a license type

Share

Related Products

Global Markets DirectFatigue - Pipeline Review, H2 2013Product ThumbnailFatigue - Pipeline Review, H2 2013, Industry ReportProduct #: 113297
GlobalData
TeleResearch
Global Markets Direct
GBI Research
MarketsandMarkets
MicroMarketMonitor
PayPal Acceptance Mark
SSL Certificate
Copyright © 2017 Global Market Analyst. All Rights Reserved